IP Library › Granted Patent US 9,005,665
Granted Patent B2
US 9,005,665 · App. 13/869,834 · Granted Apr 14, 2015

Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome

Inventors: Renukaradhya Gourapura (Wooster, OH); Varun Dwivedi (Wooster, OH); Basavaraj Binjawadagi (Wooster, OH); Jordi Torrelles (Dublin, OH)
Assignee: Ohio State Innovation Foundation
A61K39/12A61K9/14A61K35/74C07K16/10A61K2039/5252A61K2039/541A61K2039/543A61K2039/545A61K2039/552A61K2039/55594A61K2039/57C12N2770/10034C12N2770/10061
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,005,665
App. No.
13/869,834
Granted
Apr 14, 2015
Kind
B2
Abstract

Disclosed herein are methods and compositions for treating or preventing Porcine reproductive and respiratory syndrome (PRRS) infection in a subject.

Claims (16)

1. A composition comprising an inactivated porcine reproductive and respiratory syndrome virus (PRRSV) and a nanoparticle, wherein the inactivated PRRSV is entrapped within the nanoparticle, wherein the concentration of the inactivated PRRSV is 1×10 5 to 1×10 7 TCID 50 , wherein the composition further comprises an adjuvant, wherein the adjuvant is a Mycobacterium lysate.

2. The composition of claim 1 , wherein the adjuvant is a Mycobacterium tuberculosis whole cell lysate.

3. The composition of claim 1 , wherein the adjuvant is a Mycobacterium smegmatis whole cell lysate, Mycobacterium tuberculosis whole cell lysate, Mycobacterium vaccae whole cell lysate, or Mycobacterium alvei whole cell lysate.

4. The composition of claim 1 , wherein the nanoparticle is immunogenic.

5. The composition of claim 1 , wherein the nanoparticle is poly(lactide co- glycolide) (PLGA).

6. The composition of claim 5 , wherein the PLGA is 50/50 or 75/25 PLGA.

7. The composition of claim 5 , wherein the ratio of PLGA to inactivated PRRSV is about 180 mg of PLGA to about 5 mg of inactivated PRRSV.

8. The composition of claim 1 , wherein the inactivated PRRSV is inactivated by UV light or binary ethylenimine (BEI).

9. A vaccine comprising a composition of claim 1 in a carrier.

10. A method of eliciting an immune response against PRRSV in a pig comprising administering to said pig a composition of claim 1 .

11. The method of claim 10 , wherein the immune response is cross-protective against PRRSV infection.

12. A method of reducing reproductive or respiratory failure in pigs comprising the steps of:

providing a composition of claim 1 ; and administering said composition to pigs.

13. The method of claim 10 , wherein the composition or vaccine is administered intranasally.

14. The method of claim 1 , wherein the concentration of the inactivated PRRSV is 0.5×10 6 TCID 50 .

15. The method of claim 1 , wherein the concentration of the inactivated PRRSV is 2.5×10 6 TCID 50 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2014
From: GOURAPURA, RENUKARADHYA J.; DWIVEDI, VARUN; BINJAWADAGI, BASAVARAJ S.; TORRELLES, JORDI
To: OHIO STATE INNOVATION FOUNDATION
Reel/Frame 034218/0724 →
Continuity (2)
Provisional Application 61637547 · Apr 24, 2012
Related Publication 20140004193A1 · Jan 2, 2014